CS Paper Radar

Decoding Extrahepatic Targeting of Lipid Nanoparticles with Interpretable Machine Learning

Asal Mehradfar, Mohammad Shahab Sepehri, Owen Antholine, Varun Shankar, Glen S. Kwon, Salman Avestimehr, Morteza Rasoulianboroujeni

cs.CE q-bio.QMcs.LG ·submitted 2026-09-15 18:31 UTC · v1

Abstract

Lipid nanoparticles (LNPs) have transformed RNA medicine, yet their clinical utility remains constrained by predominant hepatic accumulation after systemic administration. Redirecting LNPs to extrahepatic tissues requires understanding of how lipid chemistry and formulation composition jointly govern in vivo biodistribution. Here, we develop an interpretable machine learning framework to predict hepatic versus extrahepatic LNP accumulation and identify molecular design rules for extrahepatic RNA delivery. A literature-derived dataset of 476 intravenous LNP formulations was curated from 81 studies, integrating formulation composition, lipid chemical structures, and IVIS-based biodistribution profiles. Standardized SMILES representations of ionizable lipids, helper lipids, sterols, PEGylated or polymer-conjugated lipids, additional lipids, and polymer repeat units were converted into RDKit Expert descriptors and combined with formulation-level variables to generate an 808-dimensional feature representation. Logistic regression, random forest, and XGBoost achieved ROC-AUC values of 0.839, 0.866, and 0.874, respectively. SHAP-based interpretation and consensus feature ranking revealed that ionizable-lipid descriptors dominate biodistribution prediction, while formulation composition, particularly ionizable lipid, sterol, and PEGylated/polymer-conjugated lipid fractions, contributes substantially. The top 20 consensus features retained nearly all predictive information in tree-based models. The most informative features implicated electrotopological surface properties, charge- and hydrophobicity-weighted surface areas, molecular topology, and amide/alkyl structural motifs as drivers of extrahepatic accumulation. This study establishes an interpretable, data-driven strategy for decoding LNP biodistribution and provides actionable design principles for engineering LNPs beyond the liver.

Closest papers

Nearest neighbours by meaning across the whole index.

An Explainable Machine Learning Framework for Predicting Blood-Brain Barrier Permeability Using Molecular Descriptors

cs.LG cond-mat.mtrl-sci ·2026-09-09 ·Fatemeh Mahmoudi
code/data similarity 0.56
Abstract · 19 pages, 6 figures, 4 tables. Source code and processed data are publicly available on GitHub

Blood-brain barrier (BBB) permeability is a critical determinant in the development of central nervous system therapeutics because it directly influences the ability of drug candidates to reach their target sites within the brain. In this study, an explainable machine learning framework was developed to predict BBB permeability using molecular descriptors generated from the MoleculeNet BBBP dataset with the RDKit cheminformatics toolkit. Fifteen physicochemical descriptors extracted from 2,039 compounds were used to train four supervised machine learning algorithms, including Logistic Regression, Support Vector Machine (SVM), Random Forest, and Extreme Gradient Boosting (XGBoost). Hyperparameter optimization was performed using GridSearchCV, while model interpretability was investigated using SHapley Additive exPlanations (SHAP). Among the evaluated models, the optimized XGBoost classifier achieved the best predictive performance, with an accuracy of 88.97%, a precision of 88.92%, a recall of 97.76%, an F1-score of 93.13%, and a ROC-AUC of 0.9282. Stratified five-fold cross-validation further demonstrated the robustness of the proposed model, yielding a mean ROC-AUC of 0.8982 +/- 0.0130. Feature importance and SHAP analyses consistently identified TPSA, HBD, and LogP as the most influential molecular descriptors governing BBB permeability prediction. Overall, the proposed framework provides an accurate, interpretable, and computationally efficient approach for BBB permeability prediction and may serve as a valuable tool for the early-stage screening of CNS drug candidates.

0.46

The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design

cs.AI q-bio.QMcs.LG ·2026-11-10 ·Maria Franz, N. Benjamin Erichson
published similarity 0.54
Abstract · 14 pages, 3 figures. Accepted at the AI4DD workshop (AI for Drug Discovery: Bridging the Translation Gap), NeurIPS 2026

Generative models are increasingly used to propose molecules for drug discovery. They can produce far more candidates than can be experimentally tested, making computational selection essential. Most selection methods rely on predicted molecular properties, such as potency and toxicity, but overlook how these properties translate into drug exposure at a given dose. As a result, molecules that appear promising on paper may require impractical doses or raise safety concerns. We investigate this gap by using physiologically based pharmacokinetic (PBPK) simulations to re-evaluate molecules selected from three PARP1-targeted generative pipelines. Of 60 shortlisted molecules, seven fail to achieve sufficient target exposure, while 28% of the remaining candidates show predicted safety risks at their required dose. Moreover, 85% of candidates with an achievable dose are outperformed by molecules overlooked during static selection. These findings suggest that accounting for dose and exposure can substantially change which generated molecules are considered promising for drug development.

0.32

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.54
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

Potential of Artificial Intelligence Algorithms for Identification of Relevant Diagnostic and Prognostic Biomarkers of Early-Stage Liver Cancer

cs.AI ·2026-09-14 ·Ali Bou Nassif, Darko Castven, Manar Abu Talib, Jibran Sualeh Muhammad, Ahmed Ammar Kubba +2 more
hot direction similarity 0.53
Abstract · 25 pages, 11 figures, 4 tables, under review

This study explores the use of deep learning and explainable artificial intelligence to diagnose hepatocellular carcinoma (HCC) and define effective biomarkers across five different stages of disease development using a transcriptomic biomarker HCC dataset constructed via semi-supervised learning from three source datasets. Several deep learning experiments were conducted with different feature extraction techniques and gene sets to identify the most effective features for training high-accuracy models with minimal loss. The best-performing model, using 15 selected genes with the SelectKBest algorithm, achieved 90.74% accuracy, while the model with the lowest recorded loss of 0.3187 was obtained using 20 selected genes. To address the issue of class imbalance in the dataset, a weighted training approach was conducted, and for model transparency and interpretability a SHAP-based XAI analysis provided insights into the model's decision-making, consistently finding DNAJB14 as the most influential gene. Functional validation in this study has provided compelling evidence that DNAJB14 plays an important role in the adverse properties of HCC and that its inhibition effectively reverses tumour cell migration, invasion, colony and sphere formation. The main limitation of this study is the dataset's class imbalance, and while weighted training helped mitigate this, further research and additional data are needed to guarantee model generalizability. Future studies should also explore the influence of genetic variations, environmental factors, and clinical differences on model performance across diverse populations.

0.34

Chem World: A Large-Scale Benchmark and Physics-Aware Framework for Trustworthy Molecular Property Prediction

cs.LG cs.AI ·2026-11-10 ·Tianyou Bai, Huan Wang, Mingchen Gao, Tongrui Yang, Fangyue Lin +3 more
benchmark similarity 0.52
Abstract

Molecular property prediction is fundamental to computational chemistry and drug formulation research, yet existing benchmarks remain fragmented across datasets, properties, and evaluation protocols, limiting systematic evaluation of model generalization. We introduce Chem World, a large-scale benchmark integrating 17 public datasets with over 800,000 molecular and chemical-system instances across 10 property tracks, covering single-molecule and multi-component systems, including drug solubility. Chem World provides a unified testbed for evaluating molecular representations and compositional modeling across diverse chemical properties. Building on the benchmark, we propose PACM (Physics-Aware Compositional Modeling), which combines molecular representations with composition-aware modeling and domain-specific physical constraints. Extensive experiments show that molecular language models provide strong and transferable representations, while PACM consistently improves prediction across diverse chemical systems. Chem World and our PACM-powered drug-property prediction Agent support generalizable chemical modeling and offer a foundation for AI-assisted biomedical research and drug formulation development.

0.15

Hybrid Machine Learning-Assisted Raman Spectroscopy with Generative Feature Augmentation for Pharmaceutical Identification

cs.LG cond-mat.mtrl-sci ·2026-09-18 ·Quach Thi Thai Binh, Ton Nu Quynh Trang, Thang B. Phan, Vu Thi Hanh Thu, Nguyen Tuan Hung
similarity 0.51
Abstract · 12 pages, 7 figures, 2 tables

Rapid and reliable identification of pharmaceutical residues is important for safeguarding public health, ensuring food safety, and enabling practical Raman-based screening. In this study, we propose HyMLRaman, a hybrid Raman spectroscopy framework that combines deep spectral feature extraction, generative models, and classical machine-learning classifiers to identify six pharmaceutical compounds, including amoxicillin, chloramphenicol, ciprofloxacin, tetracycline, ibuprofen, and paracetamol. Raman spectra are converted into spectral images and encoded with several deep neural-network backbones, among which EfficientNet-B3 yields the most effective representation. The resulting 1536-dimensional embeddings are then used to train downstream classifiers, including SVM, KNN, logistic regression, random forest, XGBoost, and ANN, using stratified 10-fold cross-validation. The hybrid EfficientNet-B3--SVM configuration achieves the strongest baseline performance, reaching 96.31% accuracy and a macro-F1 score of 96.36%, outperforming the standalone CNN baseline. To address limited-data conditions, a generative model, a DDPM-based feature augmentation, is introduced in a PCA-reduced EfficientNet-B3 latent space. The low-data ablation results show that DDPM augmentation provides selective benefits, particularly for KNN with reduced training fractions, and that its effect remains classifier-dependent. Finally, an application-level Raman Pharmaceutical Analyzer demonstrates the feasibility of embedding the trained model into an interactive Raman analysis workflow. These results suggest that HyMLRaman provides a practical and interpretable route for rapid Raman-based pharmaceutical screening.

0.19

Feature Selection for Tabular Foundation Models: Exploring Feature Utility in Low-Data Molecular Prediction

cs.LG ·2026-09-25 ·Yiqi Yao, Miquel Duran-Frigola
code/data similarity 0.51
Abstract · 34 pages, 13 figures, 21 tables, 11 appendices. v3: revised and expanded with held-out FS-Mol test evaluations. Code: https://github.com/ers…

Choosing features is difficult with few labeled molecules, even for a tabular foundation model that learns in context. We study this problem with TabPFN for low-data molecular property prediction, separating input width, feature meaning, and predictive usefulness while keeping contexts, query molecules, and predictor settings matched. On ADME/Tox assays from Therapeutics Data Commons, endpoint-matched assay predictions improve a compact RDKit descriptor baseline, and a provenance audit shows that most audited query molecules already occur in the predictors' training sources. Across 77 FS-Mol development tasks and 157 held-out test assays drawn from ChEMBL, broad RDKit descriptor and fingerprint families provide a strong default, rank-averaging TabPFN with support-fitted fingerprint forests improves upon both models, and learned weighting of family predictions adds further gains at a larger prediction budget. A utility-trained selector builds a traceable 16-column input from 238 sourceassay predictors, improving upon the baseline while trailing wider representations and equalwidth structural SVD coordinates. Named outputs identify what each feature predicts and where it comes from. Their usefulness for a new assay is assessed alongside the other input features, and paired removal and replacement tests measure what each selected output contributes. Together, these studies offer a protocol for evaluating feature selection, representation choice, and data provenance with a fixed tabular foundation model for few-shot molecular property prediction.

0.36

D2ML: Models for Direct-to-Biology Small Molecule Screening

cs.LG q-bio.BM ·2026-10-29 ·AkshatKumar Nigam, Neri Amara, Hillary Dequina, Dyana Kenanova, Seth Malmersjo +5 more
published similarity 0.51
Abstract · NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Direct-to-biology (D2B) screening enables rapid testing of newly synthesized molecules without purification. However, uncertain concentrations in crude mixtures and limited purified-compound measurements complicate the use of these data in machine learning. Here we show that models tailored to the structure of D2B data can improve prediction and guide the discovery of more potent and selective compounds. Our assay-aware models predict activity from single-point screens, relative potency across targets from crude dose-response assays, and absolute potency from purified-compound measurements. For crude assays, potency ratios between targets tested from the same well can retain selectivity information despite uncertain concentrations. A joint model that shares information across stages and balances their contributions to training improved predictions over separate neural networks. The largest gain was in crude dose-response selectivity prediction, where rank correlation increased from 0.27 to 0.40. In a separate experiment, independently trained models guided the selection of 84 new compounds to improve ROS1 potency while limiting activity against the anti-target TRKB. Synthesis and testing identified compounds that extended the measured Pareto front, achieving better combinations of potency and selectivity than those in the training data. The most selective new compound achieved a ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB. By comparison, the most selective training compound had a ROS1 IC50 of 20.3 nM and 79-fold selectivity. ATLAS provides the experimental setting for this approach, supporting synthesis and screening of 1,000-10,000 model-selected compounds in two- to three-week cycles. Together, these results show how assay-aware learning can use the full D2B assay sequence to guide multi-objective molecular optimization.

0.16